Last reviewed · How we verify
TQC2731 injection
TQC2731 injection is a Small molecule drug developed by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.. It is currently in Phase 3 development.
TQC2731 injection's mechanism is not publicly available.
TQC2731 injection is being studied in clinical trials for the treatment of Chronic Rhinosinusitis With Nasal Polyps, Chronic Sinusitis, Nasal Polyps, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), and Severe Asthma. The exact mechanism of TQC2731 injection is unknown, as its modality is listed as "Unknown" in ChEMBL.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | TQC2731 injection |
|---|---|
| Sponsor | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Unfortunately, there is limited information available on the exact mechanism of action of TQC2731 injection.
Approved indications
Common side effects
Key clinical trials
- Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps (PHASE3)
- A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (PHASE2)
- Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma. (PHASE2)
- A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps (PHASE2)
- A Clinical Study of TQC2731 Injection in the Treatment of Chronic Rhinosinusitis With Nasal Polyps (PHASE2)
- TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection (PHASE3)
- Phase I Clinical Trial of TQC2731 Injection (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TQC2731 injection CI brief — competitive landscape report
- TQC2731 injection updates RSS · CI watch RSS
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. portfolio CI
Frequently asked questions about TQC2731 injection
What is TQC2731 injection?
How does TQC2731 injection work?
Who makes TQC2731 injection?
What development phase is TQC2731 injection in?
Related
- Manufacturer: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing